BioSpace News Archive

Business

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2021, and recent company developments, along with a business outlook for 2022.

March 1, 2022
·
13 min read
Drug Development

Kintor Pharma Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US

Kintor Pharmaceutical Limited today announced the first patient dosing in its phase II clinical trial of KX-826 (“pyrilutamide”) in the US for the treatment of male androgenetic alopecia.

March 1, 2022
·
2 min read
Business

NeuroGenesis and Hadassah Medical Center Report Positive NF-L Biomarker Results from a Phase 2 Study in Progressive Multiple Sclerosis Treated with NG-01 Cells Therapy

NeuroGenesis and Hadassah Medical Center announced today positive results from a placebo-controlled Phase 2 clinical trial assessing the impact of NG-01 autologous proprietary subpopulation of bone marrow cells on the expression levels of NF-L.

March 1, 2022
·
6 min read
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

Enveric Biosciences today announces that it has filed its 10th Patent Cooperation Treaty (“PCT”) patent application directed to tryptamine-based derivative molecules, completing the Company’s broad series of PCT applications covering this family of compounds.

March 1, 2022
·
5 min read
Business

Quanterix Announces New Agreements with Lilly to Advance Alzheimer’s Disease Diagnosis and Treatment

Quanterix Corporation today announced it has entered into a collaboration with Eli Lilly and Company (Lilly) to advance the diagnosis, monitoring and treatment of Alzheimer’s disease.

March 1, 2022
·
5 min read
Miravo Healthcare™ Announces the Canadian Commercial Launch of Blexten® for Patients 4 Years of Age and Older*

Miravo Healthcare™ Announces the Canadian Commercial Launch of Blexten ® for Patients 4 Years of Age and Older.

March 1, 2022
·
6 min read
Business

Quanterix Announces Executive Leadership Succession Plan

Masoud Toloue, President of Quanterix and Diagnostics, to Become CEO and Join Board of Directors.

March 1, 2022
·
5 min read
Business

Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2021

Quanterix Corporation today announced financial results for the fourth quarter and twelve months ending December 31, 2021.

March 1, 2022
·
15 min read
Business

Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer

Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient on a Phase 2 study of elraglusib (9-ING-41) plus retifanlimab combined with gemcitabine/nab-paclitaxel for the treatment of patients with advanced pancreatic cancer in the first-line setting (NCT05239182).

March 1, 2022
·
4 min read
Bio NC

New Science 37® CNS Survey Confirms Growing Trend in Clinical Trials LandscapeWithin CNS indications, data suggest Agile Clinical Trials™ and decentralized approaches will become more prevalent in 2022 and beyond

Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today published new CNS (Central Nervous System) therapeutic data validating the growing trend toward decentralization as two-thirds of CNS survey respondents plan to execute an agile or decentralized clinical trial in 2022, an increase of more than 35 percent from last year.

March 1, 2022
·
6 min read